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Venture Capital Investments for Life
Sciences Start-ups in Switzerland
Pascal Gantenbein* and Nils Herold
Abstract: Despite its economic and technological importance, the Swiss life sciences sector faces severe
challenges in attracting enough venture capital for its own development. Although biotechnology and medical
technology have been the most important areas of venture financing from 1999 through 2012 according to our
own data, average investment volumes nevertheless remain on a low level of only 0.05 percent of Swiss GDP.
After 2008, there was a pronounced shift away from early-stage financing. While business angels still play an
important role at the early stage, venture capitalists are the most important investor type by volumes having their
main focus on expansion financing. The industry faces predominant challenges in securing capital availability
for entrepreneurs, in transforming the highly skewed and back-loaded payoff profile of investments into a more
stable return stream, and in defining appropriate business and collaboration models.
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1. Introduction
The economic contribution of the life
sciences sector in Switzerland is remark-
able. On the one hand, approximately
20,000 people generating a sales volume
of roughly CHF 10 billion per year work
in biotechnology and medical technol-
ogy. Including suppliers and distributors
even yields substantially higher numbers.
On the other hand, this sector features an
extraordinary density of experts contribut-
ing to a high level of innovation, which is
again a prerequisite for future growth in
Switzerland, as the development of the
pharmaceutical industry clearly docu-
ments.
In spite of this, the financing of life
sciences start-ups is a difficult task as ever
both for investors and entrepreneurs. This
is especially true in the case of venture
capital, which term is subsequently used
for equity investments in the early stage
and the expansion stage of the company
life cycle of high-technology start-ups.
Venture capital investments in life sci-
ences start-up companies in Switzerland
have experienced massive swings over
the past two decades. While in the United
States the early years of the modern life
sciences industry and respective venture
capital financing transactions date back to
the 1970s, the development in Switzerland
has substantially been lagging behind.
Even in the 1990s, venture capital invest-
ments in life sciences only played a minor
role in Switzerland, also within the class of
start-up companies.
However, this has considerably
changed: Over the past 15 years, life sci-
ences have turned to represent the by far
most important topic in the area of venture
capital investments in Swiss high-technol-
ogy firms. Our data from the SwissVenture
Capital Database at the University of Basel
show that over the period from 1999 to
2012, 57% of the CHF 6.5 billion aggre-
gate venture capital investment volume in
Swiss high-tech start-ups went into life sci-
ences. At the same time, both the propor-
tion and the absolute investment volumes
are far from being persistent on a constant
level, which poses obvious challenges to
the industry.
Against this background, three ques-
tions are of particular interest: First,
which are the typical investment patterns
and characteristics related to start-ups in
general and, notably, to those in the life
sciences industry observable over time?
Second, what are the key drivers behind
this development?And finally, how should
the industry respond to the challenges and
which strategies should companies in life
sciences adopt in order to be competitive?
Given the enormous importance of this
sector for a country’s long-term technolo-
gy leadership and future economic growth,
the answers to these questions must be rel-
evant far beyond the borderline of compa-
nies and investors in this field.
2. Dynamics of Venture Capital
Investments in Life Sciences
To better understand the dynamics of
financing transactions in the area of life
sciences, we first analyze the pattern of in-
vestments based on the data gathered in the
Swiss Venture Capital Database. Hereby,
the focus is on a) life sciences financing
compared to venture capital investments
in other industries, b) the development of
average transaction volume over time, and,
c) the relationship between biotechnology
and medical technology.
Before the millennium, investments
into biotechnology and medical technol-
ogy remained on a low level both in rela-
tive and absolute terms. Up to year 2000,
the transaction volume in Swiss high-tech
start-ups was dominated by the sectors in-
formation and communication technology
(ICT) and engineering. From that time on,
this has changed significantly. While life
sciences accounted for only 17% of total
investment volume in 1999, the ratio has
grown to 84% in 2004 and after a slight
dip in 2005 back up to even 87% in 2009.
Since then, however, the recorded financ-
ing volume has decreased to 51% in 2012.
During the same period, the average
transaction volume in life sciences venture
capital financing has massively dropped.
In 2007, the average investment amount
reached CHF 13.2 million, while the same
number almost halved to CHF 6.8 million
in 2011. This shift was primarily driven by
the biotech sector. With CHF 11.9 million,
the latter also exhibits considerably higher
average transaction volumes as opposed to
the CHF 5.7 million in the medical tech-
nology sector. Still, the average investment
volumes are by far the highest in life sci-
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ness angels, foundations, and venture capi-
talists, and c) the regional distribution of
investments.
The investment history from 1999 to
2012 documents that venture capitalists
are by far the most important investor type.
These highly professional financial inter-
mediaries raise funds from return-oriented
investors, take an active role in creating
value in the start-up companies they invest
in, and aim to maximize their financial
return by exiting the investments. Venture
capitalists provided 63% of the CHF 3.7
billion life sciences venture financing over
these years. This proportion is almost the
same for biotech and medtech; i.e. venture
capitalists are the dominant investor type
in both subsectors. Only 13% fall upon
investment companies which, unlike ven-
ture capitalists, do not manage funds and
17%were provided by industrial investors.
The latter, which are often referred to as
corporate venture capitalists, rather pursue
strategic goals than financial ones. Private
investors such as business angels only con-
tributed 5% and foundations just as little as
0.3% to the total volume.
However, this percentage figure by far
underestimates the effective importance of
private investors and foundations for the
existence of these firms. Although both
private investors and foundations exhibit
relatively small average investment lot
sizes as well as aggregate investment capi-
tal volumes, these two investor types are
extremely active and play a crucial role
especially at the very beginning of the
start-ups’ company life cycle.
Foundations on the one hand typically
limit their contribution to a maximum of
about CHF 100,000. This can neither have
a sizable impact per se in biotech nor in
medtech. However, through the competi-
tions as well as the awards that go along
with granting these funds, the start-up com-
panies obtain significant public attention
and an important recognition at a relative-
ly early stage. With an average investment
amount of CHF 1.3 million per transaction
over all sectors and CHF 2.1 million in the
case of life sciences, private investors on
the other hand invest substantially larger
sums. Furthermore, beyond the pure pro-
vision of funds, private investors typically
act as business angels and support young
companies with their advice and network.
While the statistics show that 75% of
foundations’ and 68% of private investors’
money is allocated in the early stage, ven-
ture capitalists are relatively more present
at the expansion stage. In other words, the
first step very often is done by business an-
gels, who in doing so also carry the high-
est risks, while venture capitalists take over
later. This is not to say that venture capi-
talists would be absent from early-stage
financing. Indeed, 39% of the recorded
ences compared to other high-tech sectors,
due to large-scale investments and the
more expensive R&D processes.
In general, it has to be noted that the
number of financing transactions is quite
limited. Although the database covers as
many transactions as were available, we
only register an average number of 29
larger investment transactions per year
between 1999 and 2012 in biotech and
medtech combined, whereby the latter ac-
counts for 44% of transactions.
Furthermore, the figures unveil that
there has been a remarkable shift within
life sciences in terms of venture capital in-
vestment volumes. While from 1999 until
2008, medical technology accounted for
only 19% of the total transaction volume in
life sciences, its importance grew to 51%
for the years 2009 to 2012. The analysis
therefore illustrates that investment trends
both within life sciences and in propor-
tion to other venture capital investments in
high-tech start-ups tend to persist over a
couple of years before reverting.
These conclusions are further support-
ed by data collected in the Swiss Start-up
Monitor (www.startupmonitor.ch), which
is an initiative of the Universities of St.
Gallen and Basel, the Federal Institute
of Technology in Zurich, and the Swiss
Federal Commission for Technology and
Innovation (CTI). In 2014, 23% of regis-
tered start-up companies in Switzerland
belong to life sciences. From these, 58%
are active in medical technology and diag-
nostics, 42% in biotechnology and pharma.
Fig. 1 shows the relative venture capi-
tal investment volumes into life sciences
and other types of high-tech start-ups. The
latter comprise ICT, engineering and re-
lated services. The chart also depicts the
development of the total investment vol-
umes in these sectors. As can be seen, the
boom years around 2000 attracted a lot of
capital, contributing to investment levels
that have not been reached since. On the
contrary, the average yearly venture capital
financing amount from 2001 to 2012 was
only at a level of CHF 411 million over all
high-tech sectors. Over the same time pe-
riod, the average yearly amount of venture
capital investments in Swiss life sciences
start-ups was CHF 255 million, which cor-
responds to an average of 0.05% of Swiss
GDP per year. This is an amazingly small
number given the enormous importance of
life sciences with respect to the challenges
of the health care sector, the ability to foster
technological know-how and for securing
the future existence of the pharmaceutical
sector in Switzerland.
3. Drivers of Venture Capital
Investments in Swiss Life Sciences
The patterns described in the previous
section are ultimately driven by investor
decisions. Apart from the start-up compa-
nies’ founders and their families, typical
investors are business angels, foundations,
venture capitalists, industrial investors,
and investment companies. Therefore, we
now take a closer look at a) the investor
types in life sciences, b) the roles of busi-
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Fig. 1. Relative investments in life sciences start-ups and total investment volumes (source: Swiss
Venture Capital Database, University of Basel).
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For the entrepreneurs, a fundamental
problem exists in the observed cyclicality
of investment flows. As could be seen dur-
ing the financial crisis of 2008, not only
the willingness of investors to make capi-
tal commitments has suffered. In addition,
the constricted investment volume featured
a shift from early to expansion financing.
Both effects have led to a scarcity of ven-
ture capital for the early stage. Apart from
some corporate investors, very few others
have remained during that time – a setting
which is clearly inefficient and costly for
the industry. This point is further aggravat-
ed by the fact that very few firms in bio-
technology are able to finance their R&D
expenses through self-generated cash
flows. Hence, they are heavily exposed to
external money flows.
Second, the industry exhibits a very
specific risk-return profile. Investment
risks for the research and development
years until compounds can get approved
are enormous. On average, the price tag per
compound is at CHF 1 to 2 billion nowa-
days, while the success rates are extremely
low. This also explains the ambiguous
record regarding the return history and
the high sensitivity of valuations towards
changes in the market and the basic condi-
tions. Because of this elevated risk profile,
the sector exhibits a relatively high sensi-
tivity towards changes in the overall stock
market valuation. For instance, from 2007
to 2011, the segment of listed life sciences
firms in the Swiss stock market has seen a
more pronounced decline than the overall
market. However, since the dip in 2011,
life sciences have made up for most of the
investment volume conducted by venture
capitalists during the observation period
went into early-stage financing. However,
this proportion is not constant over time.
Rather, it seems that venture capitalists
have been more active as early-stage inves-
tors some years back, while lately shifting
their focus on more mature businesses.
This is sometimes associated with a higher
degree of risk awareness, driven by the ex-
perience that due to high valuations in the
entire pharma sector after the millennium,
investment returns particularly in the bio-
tech industry have been rather disappoint-
ing in many cases.
Nonetheless, to some extent, this pat-
tern also results as a matter of course given
that in the early years of an industry, there
is also a natural prevalence of early-stage
investments. Furthermore, early-stage fi-
nancing calls for follow-up investments
in the successful cases. Not only are the
associated lot sizes larger, but quite often,
there are also respective capital commit-
ments. Interestingly, much of this shift
towards expansion financing has appeared
in the wake of the financial crisis of 2008.
During these more challenging years, the
necessary postponement of planned exits
inevitably led to less capital available for
new investments.
Overall, it has to be noted that ven-
ture capitalists play a crucial role for the
development of start-ups in life sciences.
Apart from the fact that half of the financ-
ing amount provided by venture capitalists
between 1999 and 2012 went into biotech
and another 16% into medical technology,
venture capitalists are also the dominant
investor type in life sciences.
Fig. 2 shows that 66% of the total CHF
2.7 billion investments into biotech and
57% of the total CHF 1.0 billion medtech
investments were provided by venture cap-
italists. Other investors, conversely, play a
more important role in other industries,
such as investment companies in the field
of ICT.
The intermediary function of venture
capitalists is even more material if one
considers the profile of investor demand.
For instance, it is often argued that pen-
sion funds would be eligible investors for
venture capital. This may be true from
an economic perspective given the long
time horizon of most of these institutions.
However, due to the J-curve-like return
profile and the high degree of uncertainty,
making investments in start-ups is just not
compatible with the requirements of Swiss
pension funds in terms of risk and return
profile against the background of current
regulation and the time structure of retire-
ment liabilities.
As for the regional pattern of venture
capital flows, we observe that over the past
decade, three main life sciences clusters in
Switzerland have emerged. For instance,
28% of all biotech start-up companies in
Switzerland and 12% of all companies in
medtech and diagnostics registered in the
Swiss Start-up Monitor are located in the
Basel area. While such hubs have already
existed in Basel and the Arc Lémanique,
the hub in Zurich is relatively new but
features a fast growth. In these clusters,
an above average proportion of venture
capital gets allocated to life sciences. For
example, in the Basel area, the percentage
has been up to 80–90% in some years. The
economics of life sciences clusters is based
on the observation that proximity to the
pharmaceutical industry as well as to uni-
versities and other academic institutions is
perceived to be overly beneficial for firms
in such a research intensive sector, which
also exhibits a high number of university
spin-offs.
4. Challenges for Venture Capital
Investments in Life Sciences
Despite some differences in the venture
capital flow patterns between biotechnol-
ogy and medical technology, both life sci-
ences subsectors face severe challenges.
Three aspects are predominant, namely a)
the availability of venture capital for in-
novative and promising start-ups both in
the early and the expansion stage, b) how
to manage the investment given the spe-
cific risk-return trade-off of life sciences
investments, and c) which business models
to choose for the companies active in these
industries.
57%
0%
25%
10%
7%
1%
66%
0%
8%
19%
4%
3%
Venture capitalist Foundation Investment company
Industrial investor Private investor Unknown investor
Fig. 2. Investor types
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ring) measured by
investment volume
between 1999 and
2012 (source: Swiss
Venture Capital
Database, University
of Basel).
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downturn showing above market returns.
Both has a lot to do with the fact that re-
turns from investments in life sciences,
particularly in biotech, are not generated
through cash flows from normal business
activity, but either through licensing deals
or the sale of the entire company. Hence,
potential cash flows or proceeds are heav-
ily back-loaded, requiring both a long
investment horizon and the capability to
bear losses; i.e. the readiness to accept that
maybe just one out of twenty investments
will ultimately turn out well. But, as men-
tioned, the risk is not just the investor’s in
selecting the wrong companies, it is very
much also the other way round.
Finally, a permanent question for life
sciences companies is which business
models they should optimally pursue. Due
to patent expiry of some of their block-
busters, big pharma is in need of new prod-
ucts based on top biotech research and on
partnering solutions with biotech firms.
However, it is a challenge for both sides to
find the right partner, as already collabora-
tions, let alone takeovers, create substan-
tial sunk costs. Typical ways of partnering
include joint projects, in-licensing, the
buildup of strategic shareholdings, and the
full acquisition. Therefore, the difficulty of
the industry is in choosing a suitable stra-
tegic partner, in arranging the appropriate
sequence of collaboration steps, in mutu-
ally building the necessary trust, as well as
in finding the right balance between risk
sharing and maintaining as much flexibil-
ity as possible.
5. Conclusions
There are no easy solutions at hand.
Clearly, a more efficient channeling of
venture capital into the industry would be
desirable. In particular, what is needed is
a smoothing of both capital availability
and investment returns combined with a
professional investment management.
Further, Switzerland should care for at-
tractive basic conditions in order not to in-
terfere with an efficient capital allocation.
Only this can support technology leader-
ship in this field, which is crucial for the
country’s future prosperity. And finally, it
is also the industry’s task to keep building
an internationally competitive and visible
high-technology cluster in Switzerland
that is able to attract talents and investors
from all over the world.
Received: September 9, 2014
“
Life science ventures are important to the
pharmaceutical sector and a vital element for the
industry to remain innovative. Such ventures in
Switzerland are able to draw on a strong acade-
mic and corporate talent base, a stable legal and
regulatory environment, and increasingly sophis-
ticated investors. With these advantages, it is
no surprise that Switzerland is among the most
attractive locations for new life science ventures.
Novartis remains an active investor in Swiss
start-ups through our venture fund, and also
through licensing and acquisitions.
”
Joerg Reinhardt, Chairman of the Board of Directors of Novartis AG, Basel
